Indeed, patients affected by AD, MD, and MCI showed significantly reduced circulating levels of ATG5, and this was proposed, together with Parkin, as a circulant biomarker to monitor patients with cognitive decline [56]. This evidence concerns the gene PRKN and Alzheimer disease.